These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 35061305)
1. FOXO1 cooperates with C/EBPδ and ATF4 to regulate skeletal muscle atrophy transcriptional program during fasting. Oyabu M; Takigawa K; Mizutani S; Hatazawa Y; Fujita M; Ohira Y; Sugimoto T; Suzuki O; Tsuchiya K; Suganami T; Ogawa Y; Ishihara K; Miura S; Kamei Y FASEB J; 2022 Feb; 36(2):e22152. PubMed ID: 35061305 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia. Silva KA; Dong J; Dong Y; Dong Y; Schor N; Tweardy DJ; Zhang L; Mitch WE J Biol Chem; 2015 Apr; 290(17):11177-87. PubMed ID: 25787076 [TBL] [Abstract][Full Text] [Related]
3. Regulation of autophagy and the ubiquitin-proteasome system by the FoxO transcriptional network during muscle atrophy. Milan G; Romanello V; Pescatore F; Armani A; Paik JH; Frasson L; Seydel A; Zhao J; Abraham R; Goldberg AL; Blaauw B; DePinho RA; Sandri M Nat Commun; 2015 Apr; 6():6670. PubMed ID: 25858807 [TBL] [Abstract][Full Text] [Related]
4. cAMP-dependent protein kinase inhibits FoxO activity and regulates skeletal muscle plasticity in mice. Silveira WA; Gonçalves DA; Machado J; Lautherbach N; Lustrino D; Paula-Gomes S; Pereira MG; Miyabara EH; Sandri M; Kettelhut IC; Navegantes LC FASEB J; 2020 Sep; 34(9):12946-12962. PubMed ID: 32772437 [TBL] [Abstract][Full Text] [Related]
5. Transcription factor FoxO1, the dominant mediator of muscle wasting in chronic kidney disease, is inhibited by microRNA-486. Xu J; Li R; Workeneh B; Dong Y; Wang X; Hu Z Kidney Int; 2012 Aug; 82(4):401-11. PubMed ID: 22475820 [TBL] [Abstract][Full Text] [Related]
6. Transgenic overexpression of locally acting insulin-like growth factor-1 inhibits ubiquitin-mediated muscle atrophy in chronic left-ventricular dysfunction. Schulze PC; Fang J; Kassik KA; Gannon J; Cupesi M; MacGillivray C; Lee RT; Rosenthal N Circ Res; 2005 Sep; 97(5):418-26. PubMed ID: 16051886 [TBL] [Abstract][Full Text] [Related]
7. SIRT1 protein, by blocking the activities of transcription factors FoxO1 and FoxO3, inhibits muscle atrophy and promotes muscle growth. Lee D; Goldberg AL J Biol Chem; 2013 Oct; 288(42):30515-30526. PubMed ID: 24003218 [TBL] [Abstract][Full Text] [Related]
8. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Sandri M; Sandri C; Gilbert A; Skurk C; Calabria E; Picard A; Walsh K; Schiaffino S; Lecker SH; Goldberg AL Cell; 2004 Apr; 117(3):399-412. PubMed ID: 15109499 [TBL] [Abstract][Full Text] [Related]
9. The cathepsin L gene is a direct target of FOXO1 in skeletal muscle. Yamazaki Y; Kamei Y; Sugita S; Akaike F; Kanai S; Miura S; Hirata Y; Troen BR; Kitamura T; Nishino I; Suganami T; Ezaki O; Ogawa Y Biochem J; 2010 Mar; 427(1):171-8. PubMed ID: 20088826 [TBL] [Abstract][Full Text] [Related]
10. Advanced glycation end products induce skeletal muscle atrophy and insulin resistance via activating ROS-mediated ER stress PERK/FOXO1 signaling. Du H; Ma Y; Wang X; Zhang Y; Zhu L; Shi S; Pan S; Liu Z Am J Physiol Endocrinol Metab; 2023 Mar; 324(3):E279-E287. PubMed ID: 36724125 [TBL] [Abstract][Full Text] [Related]
15. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia. Sun R; Zhang S; Hu W; Lu X; Lou N; Yang Z; Chen S; Zhang X; Yang H Am J Physiol Cell Physiol; 2016 Jul; 311(1):C101-15. PubMed ID: 27122162 [TBL] [Abstract][Full Text] [Related]
16. FoxO Transcription Factors Are Critical Regulators of Diabetes-Related Muscle Atrophy. O'Neill BT; Bhardwaj G; Penniman CM; Krumpoch MT; Suarez Beltran PA; Klaus K; Poro K; Li M; Pan H; Dreyfuss JM; Nair KS; Kahn CR Diabetes; 2019 Mar; 68(3):556-570. PubMed ID: 30523026 [TBL] [Abstract][Full Text] [Related]
17. Effects of fenofibrate and its combination with lovastatin on the expression of genes involved in skeletal muscle atrophy, including FoxO1 and its targets. Ajima H; Kai Y; Fujimaki J; Akashi S; Morita A; Ezaki O; Kamei Y; Miura S J Toxicol Sci; 2021; 46(1):11-24. PubMed ID: 33408297 [TBL] [Abstract][Full Text] [Related]
18. Regulation of muscle atrophy-related genes by the opposing transcriptional activities of ZEB1/CtBP and FOXO3. Ninfali C; Siles L; Darling DS; Postigo A Nucleic Acids Res; 2018 Nov; 46(20):10697-10708. PubMed ID: 30304480 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy. Reed SA; Sandesara PB; Senf SM; Judge AR FASEB J; 2012 Mar; 26(3):987-1000. PubMed ID: 22102632 [TBL] [Abstract][Full Text] [Related]
20. FOXO1 suppresses PGC-1β gene expression in skeletal muscles. Nakai S; Oyabu M; Hatazawa Y; Akashi S; Kitamura T; Miura S; Kamei Y FEBS Open Bio; 2020 Jul; 10(7):1373-1388. PubMed ID: 32433820 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]